CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IGC Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IGC Pharma Inc
2405 York Road, Suite 201
Phone: (301) 983-0998p:301 983-0998 LUTHERVILLE-TIMONIUM, MD  21093-2264  United States Ticker: IGCIGC
Business Summary
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aß plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aß plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aß plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
7359 Equipment rental and leasing, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Richard K.Prins 67 1/1/2012 5/22/2007
President, Chief Executive Officer, Director RamMukunda 65 1/1/2012 4/29/2005
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director ClaudiaGrimaldi 53 5/1/2022 1/1/2016
Independent Director TerryLierman 76 3/12/2024 3/12/2024
Independent Director JamesMoran 79 1/18/2022 1/18/2022

Business Names
Business Name
Cabaran Ultima Sdn Bhd
Hamsa Biopharma India Pvt. Ltd.
HH Processors, LLC
13 additional Business Names available in full report.

General Information
Number of Employees: 67 (As of 3/31/2024)
Outstanding Shares: 77,449,374 (As of 11/7/2024)
Shareholders: 44
Stock Exchange: ASE
Federal Tax Id: 202760393
Fax Number: (240) 465-0273


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024